<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mannitol (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mannitol (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mannitol (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="108771" href="/d/html/108771.html" rel="external">see "Mannitol (systemic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="109240" href="/d/html/109240.html" rel="external">see "Mannitol (systemic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F28662085"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Osmitrol;</li>
<li>Resectisol [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871965"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Osmitrol;</li>
<li>Resectisol [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F28662091"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Diuretic, Osmotic;</li>
<li>
                        Genitourinary Irrigant</li></ul></div>
<div class="block doa drugH1Div" id="F28662134"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Resectisol has been discontinued in the United States for &gt;1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5039bc61-c856-4b74-99d9-abf8a3f17814">Intracranial pressure reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracranial pressure reduction (eg, due to cerebral edema, trauma, intracerebral hemorrhage, acute ischemic stroke, hepatic encephalopathy, transtentorial herniation syndrome) (off-label dosing):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (using 20% solution):</b> 0.5 to 2 g/kg once; may repeat 0.25 to 1 g/kg per dose every 4 to 6 hours based on response and clinical status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35579034','lexi-content-ref-27654000','lexi-content-ref-34618757','lexi-content-ref-32227294','lexi-content-ref-24481284','lexi-content-ref-31999657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35579034','lexi-content-ref-27654000','lexi-content-ref-34618757','lexi-content-ref-32227294','lexi-content-ref-24481284','lexi-content-ref-31999657'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb2a3b95-1c3e-4397-a60a-e7908e8247a1">Intraocular pressure reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraocular pressure reduction:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Presurgical dosing</i>:<b> IV: </b>1.5 to 2 g/kg administered over 30 to 60 minutes 1 to 1.5 hours prior to surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Traumatic hyphema</i>:<b> IV:</b> 1.5 g/kg administered over 45 minutes twice daily for IOP &gt;35 mm Hg; may administer every 8 hours in patients with extremely high pressure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10505828']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10505828'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="78395f92-0657-4a43-be5b-1bffdb380d9a">Kidney transplant, intraoperative volume optimization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney transplant, intraoperative volume optimization (off label): Note:</b> Concentrated mannitol (ie, 20%) is preferred to optimize intravascular volume status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17081224','lexi-content-ref-3918517','lexi-content-ref-6401883']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17081224','lexi-content-ref-3918517','lexi-content-ref-6401883'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 12.5 to 25 g at kidney revascularization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Shapiro.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Shapiro.1'])">Ref</a></span>); doses up to 50 g have been studied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7482828','lexi-content-ref-3918517','lexi-content-ref-3122381','lexi-content-ref-6401883']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7482828','lexi-content-ref-3918517','lexi-content-ref-3122381','lexi-content-ref-6401883'])">Ref</a></span>). Some experts utilize 1 g/kg (maximum dose: 75 g); however, many centers utilize fixed dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Shapiro.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Shapiro.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="47710176-5012-4cbe-b008-077108680ef7">Transurethral irrigation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Transurethral irrigation: </b> Use 5% urogenital solution as required for irrigation.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991885"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Contraindicated in severe kidney impairment. Use caution in patients with underlying kidney disease. May be used to reduce the incidence of acute kidney injury when administered prior to revascularization during kidney transplantation.</p></div>
<div class="block doha drugH1Div" id="F50989262"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F28662135"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Consider initiation at lower end of dosing range.</p></div>
<div class="block dop drugH1Div" id="F28662133"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="109240" href="/d/html/109240.html" rel="external">see "Mannitol (systemic): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5039bc61-c856-4b74-99d9-abf8a3f17814">Intracranial pressure reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracranial pressure (ICP) reduction:</b> Infants, Children, and Adolescents: IV: Usual range: 0.25 to 1 g/kg/dose infused over 20 to 30 minutes; repeat as needed to maintain serum osmolality &lt;320 mOsm/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-27654000','lexi-content-ref-22217782','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-27654000','lexi-content-ref-22217782','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb2a3b95-1c3e-4397-a60a-e7908e8247a1">Intraocular pressure reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraocular pressure (IOP) reduction:</b> Infants, Children, and Adolescents: IV: 1.5 to 2 g/kg/dose infused over ≥30 minutes. <b>Note:</b> When used preoperatively, administer 60 to 90 minutes prior to surgery.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9cbbf86b-140a-410a-a24a-8c8f2fdc2d16">Traumatic hyphema, intraocular pressure reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Traumatic</b>
<b> hyphema, intraocular pressure (IOP) reduction: </b>Infants, Children, and Adolescents: IV: 1.5 g/kg/dose infused over 45 minutes twice daily for IOP &gt;35 mm Hg; may administer every 8 hours in patients with extremely high pressure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10505828']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10505828'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130187"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling for kidney impairment. Use with caution in patients with underlying renal disease, with conditions that put them at high risk for developing kidney failure, or receiving potentially nephrotoxic drugs. Use is contraindicated in patients with anuria.</p></div>
<div class="block dohp drugH1Div" id="F51130188"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F28662105"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac failure, chest pain, edema, hypertension, localized phlebitis, palpitations, peripheral edema, tachycardia, thrombophlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Chills, coma, confusion, dizziness, headache, increased intracranial pressure (rebound), lethargy, malaise, pain, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, localized erythema, localized rash, pruritus, skin necrosis, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration, fluid and electrolyte disturbance, hyperkalemia, hypernatremia, hypervolemia, hypokalemia, hyponatremia, hypovolemia, increased thirst, metabolic acidosis, metabolic alkalosis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Anuria, azotemia, diuresis, hematuria, oliguria, osmotic nephrosis, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemoconcentration</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local inflammation, local pain, local pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arm and/or wrist pain, asthenia, muscle rigidity, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, pulmonary congestion, pulmonary edema, rhinitis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Acute renal failure, anaphylaxis, central nervous system toxicity, dyspnea, hypersensitivity reaction, hypotension</p></div>
<div class="block coi drugH1Div" id="F28662102"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Hypersensitivity to mannitol or any component of the formulation; anuria; severe hypovolemia; active intracranial bleeding except during craniotomy; preexisting severe pulmonary vascular congestion or pulmonary edema.</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary irrigation solution: Anuria.</p></div>
<div class="block war drugH1Div" id="F28662103"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vesicant (at concentrations &gt;5%); ensure proper catheter or needle position prior to and during IV infusion. Avoid extravasation of IV infusions; may cause compartment syndrome. Administration into a large central vein is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid/electrolyte imbalance: May cause hypervolemia and electrolyte disturbances; monitor for new onset or worsening cardiac or pulmonary congestion. Also may cause profound diuresis with fluid and electrolyte loss; close medical supervision and dose evaluation are required. Correct electrolyte disturbances; adjust dose to avoid dehydration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Serious hypersensitivity reactions (eg, anaphylaxis), including fatalities, have been reported. Discontinue mannitol immediately if hypersensitivity reaction develops and treat accordingly.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: May cause kidney dysfunction, especially with high doses; use caution in patients taking other nephrotoxic agents, with sepsis, or preexisting kidney disease. To minimize adverse kidney effects, monitor serum osmolality or osmolar gap (NCCS [Cook 2020]). Discontinue mannitol if acute kidney injury develops.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Do not administer mannitol solutions simultaneously with blood due to the possibility of pseudoagglutination or hemolysis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac and pulmonary: Mannitol may initially worsen pulmonary edema or heart failure by causing hypervolemia before diuresis ensues. Do not administer large volumes of mannitol to patients with preexisting severe pulmonary edema or heart failure. Discontinue mannitol if cardiac or pulmonary status worsens.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cerebral edema: In patients being treated for cerebral edema, mannitol may accumulate in the brain (causing rebound increases in intracranial pressure) if circulating for long periods of time as with continuous infusion; intermittent boluses preferred. If hypotension occurs, monitor cerebral perfusion pressure; reassess dose and mannitol therapy if there is a decrease in cerebral perfusion pressure.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: CNS toxicity (eg, coma, confusion, lethargy) may occur; risk may be increased in patients with impaired kidney function or with concomitant use of neurotoxic drugs. Discontinue mannitol if CNS toxicity develops.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution. In patients with severe impairment; do not use until adequacy of kidney function and urine flow is established.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878804"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Mannitol may increase cerebral blood flow, increase the risk of postoperative bleeding in neurosurgical patients, and worsen intracranial hypertension in children who develop generalized cerebral hyperemia during the first 24 to 48 hours after traumatic brain injury. </p></div>
<div class="block prod-avail drugH1Div" id="F57121889"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Resectisol has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F28662152"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Osmitrol: 5% (1000 mL [DSC]); 10% (500 mL); 15% (500 mL [DSC]); 20% (250 mL, 500 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20% (500 mL); 25% (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20% (250 mL, 500 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Irrigation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Resectisol: 5% (2000 mL [DSC])</p></div>
<div class="block geq drugH1Div" id="F28662089"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F28662154"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Mannitol Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20% (per mL): $0.05 - $0.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25% (per mL): $0.07 - $0.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Osmitrol Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10% (per mL): $0.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20% (per mL): $0.24</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871966"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Osmitrol: 10% (1000 mL); 20% (500 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20% (500 mL); 25% (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Irrigation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Resectisol: 5% ([DSC])</p></div>
<div class="block adm drugH1Div" id="F28662138"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Concentration and rate of administration depends on indication/severity. Use of an administration set with a final in-line filter (eg, ≤5 micron) is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33790482','lexi-content-ref-WHO.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33790482','lexi-content-ref-WHO.1','lexi-content-ref-Manu.1'])">Ref</a></span>). For cerebral edema or elevated intracranial pressure, administer over 10 to 30 minutes; for patients with high risk for cerebral herniation, use faster administration rates (over ~10 minutes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24481284','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24481284','lexi-content-ref-Manu.1'])">Ref</a></span>). Inspect for crystals prior to administration. If crystals are present, redissolve by warming solution. Do not place mannitol 25% injection in PVC bags; a white flocculent precipitate may form from contact with PVC surfaces. Do not administer simultaneously with blood due to the possibility of pseudoagglutination or hemolysis. If coadministration with blood is essential, at least 20 mEq sodium chloride should be added to each liter of mannitol.</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">Vesicant (at concentrations &gt;5%); ensure proper catheter or needle position prior to and during IV infusion. Avoid extravasation of IV infusions. Administration into a large central vein is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave needle/cannula in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate hyaluronidase antidote (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hyaluronidase:</i>
<b>Intradermal or SUBQ:</b> Inject a total of 1 mL (15 units/mL) as 5 separate 0.2 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer IV through the infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Irrigation: Administer using only the appropriate transurethral urologic instrumentation.</p></div>
<div class="block admp drugH1Div" id="F52614608"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Administer IV only; do not administer IM or SUBQ. Central line preferred. Use of an inline filter set (≤5 microns) is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33790482','lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33790482','lexi-content-ref-WHO.1'])">Ref</a></span>). Inspect for crystals prior to administration; if crystals are present, redissolve by warming solution; see manufacturer labeling for details. Inspect for particulates or discoloration; if particulates or discoloration, discard bag. Do not place mannitol 25% injection in PVC bags; a white flocculent precipitate may form from contact with PVC surfaces. Do not administer with blood; pseudoagglutination or hemolysis of red blood cells may occur. Infusion rate is dependent upon indication:</p>
<p style="text-indent:-2em;margin-left:4em;">Cerebral edema or increased intracranial pressure: Administer over 20 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Increased intraocular pressure: Administer over ≥30 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Traumatic hyphema: Administer over 45 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10505828']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10505828'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant (at concentrations &gt;5%); ensure proper catheter or needle position prior to and during IV infusion. Avoid extravasation of IV infusions. If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (see Management of Drug Extravasations for more details); remove needle/cannula; apply cold compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913'])">Ref</a></span>); elevate extremity.</p></div>
<div class="block use drugH1Div" id="F28662095"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Reduction of increased intracranial pressure (associated with cerebral edema and/or brain mass); reduction of increased intraocular pressure</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary irrigation solution: Irrigation in transurethral prostatic resection or other transurethral surgical procedures</p></div>
<div class="block off-label drugH1Div" id="F28662096"><span class="drugH1">Use: Off-Label: Adult</span><p>Kidney transplant, intraoperative volume optimization</p></div>
<div class="block mst drugH1Div" id="F28662080"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Osmitrol may be confused with esmolol</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F28662112"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F28662109"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amikacin Liposome (Oral Inhalation): May enhance the nephrotoxic effect of Mannitol (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Mannitol (Systemic) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arsenic Trioxide: Osmotic Diuretics may enhance the QTc-prolonging effect of Arsenic Trioxide.  Management: When possible, avoid concurrent use of arsenic trioxide with drugs that can cause electrolyte abnormalities, such as the osmotic diuretics.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Osmotic Diuretics may decrease the serum concentration of Lithium.  Management: Consider temporarily discontinuing use of osmotic diuretics during coadministration with lithium. If coadministration is required, monitor lithium concentrations and for signs of lithium toxicity frequently.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Mannitol (Systemic) may enhance the therapeutic effect of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Diuretics may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobramycin (Oral Inhalation): Mannitol (Systemic) may enhance the nephrotoxic effect of Tobramycin (Oral Inhalation). <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F28662099"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Mannitol crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Outcome information following surgical use in pregnancy is limited; amniotic fluid volume may be decreased (Handlogten 2015; Kazemi 2014).</p></div>
<div class="block brc drugH1Div" id="F28662101"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if mannitol is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Other sources consider mannitol to be compatible with breastfeeding (WHO 2002).</p></div>
<div class="block mop drugH1Div" id="F28662144"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Kidney function; cardiac and pulmonary function; urine output; intravascular volume status; serum electrolytes, serum osmolality (measured); osmolar gap; acid-base status; serum glucose; intracranial pressure (if applicable). Monitor infusion site.</p>
<p style="text-indent:-2em;margin-left:2em;">For treatment of cerebral edema and intracranial pressure, some suggest monitoring osmolar gap as a surrogate marker for mannitol accumulation to evaluate for the risk of acute kidney injury (NCCS [Cook 2020]). Others suggest maintaining serum osmolality &lt;320 mOsm/kg due to the potential risk of acute kidney injury; however, this threshold may be exceeded if clinically necessary (Grape 2012; Rabenstein 2006).</p></div>
<div class="block pha drugH1Div" id="F28662120"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Produces an osmotic diuresis by increasing the osmotic pressure of glomerular filtrate, which inhibits tubular reabsorption of water and electrolytes and increases urinary output . Mechanism of action in reduction of intracranial pressure (ICP) is less clear. However, it is thought that mannitol reduces ICP by reducing blood viscosity which transiently increases cerebral blood flow and oxygen transport and constricts pial arterioles. This in turn reduces cerebral blood volume and ICP. Furthermore, mannitol reduces ICP by withdrawing water from the brain parenchyma and excretes water in the urine (Allen 1998; BTF [Carney 2017]).</p></div>
<div class="block phk drugH1Div" id="F28662122"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Diuresis: 1 to 3 hours; Reduction in intracranial pressure: ~15 to 30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Reduction in intracranial pressure: 1.5 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 17 L; remains confined to extracellular space (except in extreme concentrations); does not penetrate the blood-brain barrier (generally, penetration is low).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minimally hepatic to glycogen.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 0.5 to 2.5 hours; ~36 hours in acute kidney injury and end-stage kidney failure.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~80% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F57840910"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Altered kidney function: Elimination half-life is ~36 hours in patients with acute kidney injury and end-stage kidney failure. In patients with kidney impairment receiving hemodialysis, half-life elimination reduced to ~6 hours; in patients receiving peritoneal dialysis, half-life elimination reduced to ~21 hours.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F46972187"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Osmitrol</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Manitol norgreen | Solucion de manitol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Mannit</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Mannitol/osmitrol</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Manisol | Mannisol | Menitol | Osmosal</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Mannitol 15% baxter</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Endonitol | Hypofarma manitol | Manitol | Manitol baxter | Solucao de manitol | Solucao de manitol equiplex</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Mannitol braun</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Pu ke</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Manitol | Osmorin Manitol | Osmotrol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ardeaosmosol | Ardeaosmosol ma | Infusio mannitoli | Manit | Manitol viaflo | Osmofundin n</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Deltamannit | Mannit | Thomaemannit</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Acrosmosol | Manitol | Osmorol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Manitol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Mannit</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Mannitol water</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Apiros manitol | Manitol baxter | Manitol mein | Manitul vitulia | Osmofundina concentrada | Suero manitol vitulia</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Mannitol baxter | Mannitol braun | Mannitol Fresenius Kabi | Mannitol medipolar</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Mannitol aguettant | Mannitol b.braun | Mannitol baxter | Mannitol bieffe | Mannitol cooper | Mannitol fresenius | Mannitol lavoisier | Mannitol macopharm</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Flowfusor mannitol | Intravenous mannitol | Osmitrol | Polyfusor mannitol | Trav mannitol(osm)</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Mannitol/bradex | Mannitol/fresenius</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Mannitol in water</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Manit | Manitol HZTM</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Mannisol | Mannitol bieffe | Mannitoli Imuna | Mannozym</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Infusan M | Manitol</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">P tol</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Isotol | Mannistol | Mannitolo | Sol Mannitolo</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">D mannitol fuso | Manitol taiho | Maniton s | Mannigen | Mannit t | Mannite kyowa hakko | Mannitol daiichi | Mannitol kawasumi | Mannitol kobayashi | Mannitol Kowa | Mannitol kyosei | Mannitol nichiiko | Mannitol nikken | Mannyl</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Infusol M10 | Infusol M20 | Osmosol | Osmosteril</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Daihan d mannitol | Inno.n 15% mannitol | Inno.n 20% mannitol | Jw 15% mannitol | Jw 20% mannitol | Jw 25% mannitol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Mannisol a | Mannisol b | Mannit</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Manit | Mannit</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Manitol | Osmokab | Osmorol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Infusol M10 | Infusol M20</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Unimann</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Osmosteril</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Mannitol baxter viaflo</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Osmitrol c water</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Demanitol | Diurecide | Manitol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Osmitrol</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Alimanit | Manitol | Mannitozaf | Medisol mannitol | Osmofundin | Osmotol | Revasol m</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Manitol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">D manitol sanderson | Manitol demotek | Manitol icu vita | Solucion de d manitol roux ocefa | Solucion de manitol b.braun | Solucion de manitol fusa</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Osmofundin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Mannit</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Mannitol baxter viaflo | Mannitol Fresenius Kabi</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Manit</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Mannitol Viaflo | Osmofundin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Maniton | Mannitol 20% a.n.b | Mannitol thai otsu</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Mannitol mediflex | Neofleks Mannitol | Polifleks mannitol | Rezosel</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anol | Maniton | Sunnytol</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Mannit</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Abtol | Mannilife</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Manitol</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Manitol</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">20 m | Intramed mannitol | Sabax osmitrol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31999657">
<a name="31999657"></a>Alam HB, Vercruysse G, Martin M, et al; Western Trauma Association Critical Decisions in Trauma Committee. Western Trauma Association critical decisions in trauma: management of intracranial hypertension in patients with severe traumatic brain injuries. <i>J Trauma Acute Care Surg</i>. 2020;88(2):345-351. doi:10.1097/TA.0000000000002555<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/31999657/pubmed" id="31999657" target="_blank">31999657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9700443">
<a name="9700443"></a>Allen CH and Ward JD. An evidence-based approach to management of increased intracranial pressure. <i>Crit Care Clin. </i>1998;14(3):485-496.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/9700443/pubmed" id="9700443" target="_blank">9700443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18203044">
<a name="18203044"></a>Badjatia N, Carney N, Crocco TJ, et al, “Guideline for Prehospital Management of Traumatic Brain Injury 2nd Edition,” <i>Prehosp Emerg Care</i>, 2008, 12(Suppl 1):1-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/18203044/pubmed" id="18203044" target="_blank">18203044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BTF.1">
<a name="BTF.1"></a>Brain Trauma Foundation, "Guidelines for the Field Management of Combat-Related Head Trauma," 2005. Available at http://www.braintrauma.org
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BTF.2">
<a name="BTF.2"></a>Brain Trauma Foundation, "Guidelines for the Management of Severe Traumatic Brain Injury, 4th ed," 2016. Available at https://braintrauma.org/uploads/03/12/Guidelines_for_Management_of_Severe_TBI_4th_Edition.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17511539">
<a name="17511539"></a>Bratton SL, Chestnut RM, Ghajar J, et al, “Guidelines for the Management of Severe Traumatic Brain Injury. II. Hyperosmolar Therapy,” <i>J Neurotrauma</i>, 2007, 24(Suppl 1):14-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/17511539/pubmed" id="17511539" target="_blank">17511539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17478736">
<a name="17478736"></a>Broderick J, Connolly S, Feldmann E, et al, “Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group,” <i>Stroke</i>, 2007, 38(6):2001-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/17478736/pubmed" id="17478736" target="_blank">17478736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27654000">
<a name="27654000"></a>Carney N, Totten AM, O'Reilly C, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. <i>Neurosurgery</i>. 2017;80(1):6-15. doi: 10.1227/NEU.0000000000001432<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/27654000/pubmed" id="27654000" target="_blank">27654000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32227294">
<a name="32227294"></a>Cook AM, Morgan Jones G, Hawryluk GWJ, et al. Guidelines for the acute treatment of cerebral edema in neurocritical care patients. <i>Neurocrit Care</i>. 2020;32(3):647-666. doi:10.1007/s12028-020-00959-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/32227294/pubmed" id="32227294" target="_blank">32227294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10505828">
<a name="10505828"></a>Crouch ER Jr and Crouch ER. Management of traumatic hyphema: Therapeutic options. <i>J Pediatr Ophthalmol Strabismus</i>. 1999;36(5):238-250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/10505828/pubmed" id="10505828" target="_blank">10505828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Erstad.1">
<a name="Erstad.1"></a>Erstad B. Critical care pharmacotherapy. Lenexa, KS: American College of Clinical Pharmacy; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15071390">
<a name="15071390"></a>García-Morales EJ, Cariappa R, Parvin CA, Scott MG, Diringer MN. Osmole gap in neurologic-neurosurgical intensive care unit: Its normal value, calculation, and relationship with mannitol serum concentrations. <i>Crit Care Med</i>. 2004;32(4):986-991.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/15071390/pubmed" id="15071390" target="_blank">15071390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22955194">
<a name="22955194"></a>Grape S, Ravussin P. PRO: osmotherapy for the treatment of acute intracranial hypertension. <i>J Neurosurg Anesthesiol.</i> 2012;24(4):402-406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/22955194/pubmed" id="22955194" target="_blank">22955194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35579034">
<a name="35579034"></a>Greenberg SM, Ziai WC, Cordonnier C, et al; American Heart Association/American Stroke Association. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2022;53(7):e282-e361. doi:10.1161/STR.0000000000000407<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/35579034/pubmed" id="35579034" target="_blank">35579034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25899274">
<a name="25899274"></a>Handlogten KS, Sharpe EE, Brost BC, Parney IF, Pasternak JJ. Dexmedetomidine and mannitol for awake craniotomy in a pregnant patient. <i>Anesth Analg</i>. 2015;120(5):1099-1103.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/25899274/pubmed" id="25899274" target="_blank">25899274</a>]</span>
<span class="doi">10.1213/ANE.0000000000000710</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33790482">
<a name="33790482"></a>Ipema HJ, Zacher JM, Galka E, et al. Drugs to be used with a filter for preparation and/or administration-2019. <i>Hosp Pharm</i>. 2021;56(2):81-87. doi:10.1177/0018578719867660<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/33790482/pubmed" id="33790482" target="_blank">33790482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24296540">
<a name="24296540"></a>Kazemi P, Villar G, Flexman AM. Anesthetic management of neurosurgical procedures during pregnancy: a case series. <i>J Neurosurg Anesthesio</i>l. 2014;26(3):234-240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/24296540/pubmed" id="24296540" target="_blank">24296540</a>]</span>
<span class="doi">10.1097/ANA.0000000000000029</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Morris.1">
<a name="Morris.1"></a>
<i>Kidney Transplantation: Principles and Practice</i>, 6th ed, Morris PJ and Knechtle SJ, eds, Philadelphia, PA: Saunders, 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22217782">
<a name="22217782"></a>Kochanek PM, Carney N, Adelson PD, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents -- second edition. <i>Pediatr Crit Care Med</i>. 2012;13(Suppl 1):1-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/22217782/pubmed" id="22217782" target="_blank">22217782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34618757">
<a name="34618757"></a>Liotta EM. Management of cerebral edema, brain compression, and intracranial pressure. <i>Continuum (Minneap Minn)</i>. 2021;27(5):1172-1200. doi:10.1212/CON.0000000000000988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/34618757/pubmed" id="34618757" target="_blank">34618757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Mannitol injection [prescribing information]. Lake Forest, IL: Hospira; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.2">
<a name="Hospira.2"></a>Mannitol intravenous injection 25% [prescribing information]. Lake Forest, IL: Hospira, Inc; January 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Miller.1">
<a name="Miller.1"></a>Miller RD, Fleisher LA, Wiener-Kronish JP, et al, eds, Miller’s Anesthesia, 7th ed, Philadelphia: Churchill Livingstone, 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Osmitrol.1">
<a name="Osmitrol.1"></a>Osmitrol (mannitol) solution for injection [prescribing information]. Deerfield, IL: Baxter; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7606581">
<a name="7606581"></a>Palmquist KL, Quattrocchi FP, and Looney LA, “Compatibility of Furosemide With 20% Mannitol,” <i>Am J Health Syst Pharm</i>, 1995, 52(6):648,50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/7606581/pubmed" id="7606581" target="_blank">7606581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10961491">
<a name="10961491"></a>Procaccio F, Stocchetti N, Citerio G, et al, “Guidelines for the Treatment of Adults With Severe Head Trauma (Part II). Criteria for Medical Treatment,” <i>J Neurosurg Sci</i>, 2000, 44(1):11-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/10961491/pubmed" id="10961491" target="_blank">10961491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16534443">
<a name="16534443"></a>Rabinstein AA, "Treatment of Cerebral Edema," <i>Neurologist</i>, 2006, 12(2):59-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/16534443/pubmed" id="16534443" target="_blank">16534443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi: 10.1002/phar.1396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24481284">
<a name="24481284"></a>Ropper AH. Management of raised intracranial pressure and hyperosmolar therapy. <i>Pract Neurol</i>. 2014;14(3):152-158. doi:10.1136/practneurol-2014-000811<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/24481284/pubmed" id="24481284" target="_blank">24481284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7482828">
<a name="7482828"></a>Salahi H, Malek Hosseini SA, Ahmad E, Nezakatgoo N, Javid R, Ghahramani N. Mannitol infusion and decreased incidence of allograft acute renal failure. <i>Transplant Proc</i>. 1995;27(5):2569.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/7482828/pubmed" id="7482828" target="_blank">7482828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17081224">
<a name="17081224"></a>Schnuelle P, Johannes van der Woude F. Perioperative fluid management in renal transplantation: a narrative review of the literature. <i>Transpl Int</i>. 2006;19(12):947-959. doi:10.1111/j.1432-2277.2006.00356.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/17081224/pubmed" id="17081224" target="_blank">17081224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shapiro.1">
<a name="Shapiro.1"></a>Shapiro R. Kidney transplantation in adults: overview of the surgery of deceased donor kidney transplantation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 18, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs, Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11094698">
<a name="11094698"></a>Sprung J, Kapural L, Bourke DL, et al, "Anesthesia for Kidney Transplant Surgery," <i>Anesthesiol Clin North America</i>, 2000, 18(4):919-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/11094698/pubmed" id="11094698" target="_blank">11094698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy.</i> 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3918517">
<a name="3918517"></a>Tiggeler RG, Berden JH, Hoitsma AJ, Koene RA. Prevention of acute tubular necrosis in cadaveric kidney transplantation by the combined use of mannitol and moderate hydration. <i>Ann Surg</i>. 1985;201(2):246-251. doi:10.1097/00000658-198502000-00020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/3918517/pubmed" id="3918517" target="_blank">3918517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34412911">
<a name="34412911"></a>van de Laar SC, Schouten GN, IJzermans JNM, Minnee RC. Effect of mannitol on kidney function after kidney transplantation: a systematic review and meta-analysis. <i>Transplant</i>
<i>Proc</i>. 2021;53(7):2122-2132. doi:10.1016/j.transproceed.2021.07.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/34412911/pubmed" id="34412911" target="_blank">34412911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3122381">
<a name="3122381"></a>van Valenberg PL, Hoitsma AJ, Tiggeler RG, Berden JH, van Lier HJ, Koene RA. Mannitol as an indispensable constituent of an intraoperative hydration protocol for the prevention of acute renal failure after renal cadaveric transplantation. <i>Transplantation</i>. 1987;44(6):784-788. doi:10.1097/00007890-198712000-00012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/3122381/pubmed" id="3122381" target="_blank">3122381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6401883">
<a name="6401883"></a>Weimar W, Geerlings W, Bijnen AB, et al. A controlled study on the effect of mannitol on immediate renal function after cadaver donor kidney transplantation. <i>Transplantation</i>. 1983;35(1):99-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/6401883/pubmed" id="6401883" target="_blank">6401883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO), "18th Expert Committee on the Selection and Use of Essential Medicines: review of the role of mannitol in the therapy of children," 2011. Available at http://www.who.int/selection_medicines/committees/expert/18/applications/16_Mannitol_review_EMLc.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/.</div>
</li></ol></div><div id="topicVersionRevision">Topic 109078 Version 149.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
